Biomerica, Inc. (NASDAQ:BMRA) Short Interest Down 45.3% in December

Biomerica, Inc. (NASDAQ:BMRA) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 782,800 shares, a decrease of 45.3% from the November 30th total of 1,430,000 shares. Based on an average daily volume of 859,100 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Biomerica stock. Perritt Capital Management Inc bought a new stake in Biomerica, Inc. (NASDAQ:BMRA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 70,000 shares of the company’s stock, valued at approximately $31,000. Perritt Capital Management Inc owned 0.42% of Biomerica as of its most recent filing with the Securities and Exchange Commission (SEC). 22.28% of the stock is currently owned by institutional investors and hedge funds.

Biomerica Price Performance

NASDAQ:BMRA traded down $0.01 during midday trading on Friday, reaching $0.32. The stock had a trading volume of 162,170 shares, compared to its average volume of 399,510. The stock has a market capitalization of $5.31 million, a P/E ratio of -0.85 and a beta of -1.10. Biomerica has a 1-year low of $0.24 and a 1-year high of $1.35. The firm’s fifty day simple moving average is $0.33 and its 200-day simple moving average is $0.36.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings results on Tuesday, October 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. Biomerica had a negative net margin of 111.89% and a negative return on equity of 84.62%. The business had revenue of $1.81 million during the quarter.

Biomerica Company Profile

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.